A Phase II Study of Pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC

অনুযায়ী Lisberg, A, Cummings, A, Goldman, JW, Bornazyan, K, Reese, N, Wang, T, Coluzzi, P, Ledezma, B, Mendenhall, M, Hunt, J, Wolf, B, Jones, B, Madrigal, J, Horton, J, Spiegel, M, Carroll, J, Gukasyan, J, Williams, T, Sauer, L, Wells, C, Hardy, A, Linares, P, Lim, C, Ma, L, Adame, C, Garon, EB
প্রকাশিত J Thorac Oncol (2018)